Daraprim Pricing: A Case Study on Market Failure and Implications
VerifiedAdded on 2023/04/24
|5
|791
|321
Case Study
AI Summary
This case study delves into the market failure surrounding the antibiotic drug Daraprim, focusing on the actions of Turing Pharmaceuticals AG and its CEO, Martin Shkreli, who drastically increased the drug's price by 5000%. The analysis highlights the company's concentrated market power and the resulting exploitation of customers who had limited alternatives. The implications of this market failure include financial strain on patients, potential health complications from using less effective alternative treatments, and rejection from nursing homes due to the high cost of Daraprim. The case study also touches on the challenges faced by competitors attempting to enter the market with alternative drugs, as the original drug's reputation and market dominance made it difficult to gain traction, ultimately leading to market instability and patient suffering. Desklib provides resources for students to explore similar case studies and assignments.
1 out of 5